|Articles|May 29, 2012
Sanofi, Novo, Lilly Shape up for Big Insulin Fight
Advertisement
Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.
Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- More Effective CKD Strategy Could Have Health, Societal Benefits
September 22nd 2025
- Antifibrotic Therapy Effective for Certain Patients With PPF
September 22nd 2025